위암 : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장)(2025-2035년)

Global Gastric Cancer Market Outlook

Thelansis's "Global Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Gastric Cancer Overview

Gastric cancer is the fifth most common malignancy and third leading cause of cancer mortality globally, arising predominantly as adenocarcinoma from the gastric mucosa, with Helicobacter pylori infection, dietary carcinogens, tobacco, obesity, and hereditary syndromes including CDH1 germline mutations constituting principal aetiological drivers. Molecular classification encompasses EBV-positive, microsatellite instability-high, chromosomally unstable, and genomically stable subtypes, each carrying distinct therapeutic implications. HER2 amplification occurs in approximately 15-20% of gastric and gastroesophageal junction adenocarcinomas, representing a critical actionable biomarker. Patients present with epigastric pain, dysphagia, early satiety, weight loss, and anaemia, with many diagnosed at advanced stages given insidious onset. Upper endoscopy with biopsy establishes histological diagnosis, while CT staging, PET imaging, and laparoscopic staging address metastatic and peritoneal disease assessment. Comprehensive molecular profiling encompassing HER2, MSI, PD-L1 CPS, and FGFR2 status is mandatory at diagnosis. Perioperative FLOT chemotherapy is the established standard for resectable disease. Advanced HER2-positive gastric cancer is addressed with trastuzumab combined with chemotherapy, with trastuzumab deruxtecan demonstrating transformative second-line efficacy in the DESTINY-Gastric trials. Nivolumab combined with chemotherapy is the established frontline standard for HER2-negative advanced disease with CPS of 5 or above. Zolbetuximab, targeting CLDN18.2, combined with chemotherapy represents a significant newly approved frontline advance for CLDN18.2-positive tumours. MSI-H disease benefits from pembrolizumab immunotherapy. Prognosis remains poor in advanced disease; multidisciplinary tumour board evaluation, nutritional support, and early palliative integration are indispensable to patient-centred care.

Key Highlights

• In Germany, survival-adjusted prevalent Gastric Cancer cases are projected to increase from 120,844 in 2025 to 129,241 by 2035.
• Gastric cancer continues to impose significant clinical burden due to late-stage diagnosis.
• HER2-targeted therapies and immunotherapies are increasingly influencing treatment paradigms.
• Unmet need remains high in advanced and metastatic disease management.

Market Overview

• The Spain Gastric Cancer market is projected to grow from USD 220 million in 2025 to USD 580 million by 2035.
• Growth is supported by expanding biomarker testing and adoption of targeted oncology therapies.
• Pipeline therapies including ADCs and immunotherapy combinations are expected to accelerate market expansion.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp & Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome & Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences (Nanjing), Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)